Position in NVS
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$37,676,550
+$21,995,631 QoQ
Shares Held
246,655
+116.9% QoQ
Ownership
0.013%
of shares outstanding
% of Portfolio
0.01%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2021
8 quarters on record
Voting authority
Sole 0.5246194076746873.ToString("F0")%
Shared 99.47538059232531.ToString("F0")%
None 0.ToString("F0")%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Mar 31, 2026MASSACHUSETTS FINANCIAL SERVICES CO /MA/ holds $7,300,763,534 across 12 Drug Manufacturers - General names. NVS ranks #7 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
13,434,302 | $3,283,880,778 | |
| 2 | PFE |
Pfizer Inc
|
56,911,830 | $1,598,084,183 | |
| 3 | ABBV |
AbbVie Inc.
|
5,610,330 | $1,220,190,668 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
6,281,609 | $875,467,841 | |
| 5 | BIIB |
Biogen Inc.
|
720,629 | $132,112,911 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
1,050,815 | $63,731,927 | |
| 7 | NVS |
Novartis AG
This page
|
246,655 | $37,676,550 | |
| 8 | MRK |
Merck & Co., Inc.
|
271,829 | $32,698,308 |
All Filings in NVS
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $37,676,550 | 246,655 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $15,680,919 | 113,737 | Shares | Sole | 2026-01-22 | |
| 2025-09-30 | $12,745,131 | 99,385 | Shares | Sole | 2025-10-29 | |
| 2025-06-30 | $9,013,791 | 74,488 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $4,453,736 | 39,951 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $1,924,012 | 19,772 | Shares | Sole | 2025-02-12 | |
| 2022-03-31 | $1,384,344 | 15,776 | Shares | Defined | 2022-05-11 | |
| 2021-12-31 | $1,274,700 | 14,573 | Shares | Defined | 2022-02-10 | |
| No filing history on record for this holder in this stock. | ||||||